Novavax (NASDAQ: NVAX) fell behind in the original coronavirus vaccine race as rivals Pfizer and Moderna brought their products to market. The biotech launched its vaccine a year-and-a-half later in the U.S. and therefore missed out on the biggest revenue opportunity. As a result, the shares dropped and have failed to truly rebound. This year, they've lost 28%.

But all isn't lost. Coronavirus vaccines still are needed, and the market today is making an important shift. It's no longer a pandemic-style market involving people rushing out to get shots. Instead, it's following the flu vaccine market with the idea that people will get an annual vaccine -- and that should lead to recurrent revenue for vaccine makers including Novavax.

Does this make the struggling biotech a buy?

Continue reading

Source Fool.com